Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment

Neurosci Lett. 2016 Oct 6:632:104-8. doi: 10.1016/j.neulet.2016.08.045. Epub 2016 Aug 26.

Abstract

Although amnestic mild cognitive impairment (aMCI) with high cerebral deposition of amyloid-beta proteins (Aβ) could be classified as a prodromal state of Alzheimer's disease (AD) dementia, aMCI with the absence of or very little cerebral Aβ deposition is likely related to other pathophysiological processes. Thus, the present study aimed to investigate the differential patterns of regional cerebral glucose metabolism (rCMglu) according to the level of Aβ burden in the brains of patients with aMCI. This study included 25 patients with aMCI and 33 cognitively normal (CN) elderly individuals who underwent a comprehensive clinical examination, (11)C-labelled Pittsburgh Compound B (PiB) positron emission tomography (PET) scans, and (18)F-fluorodeoxyglucose (FDG) PET scans. Based on cerebral PiB retention, the aMCI subjects were divided into low Aβ (aMCI-, n=10) and high Aβ (aMCI+, n=15) subgroups, and differences in rCMglu among the CN group and aMCI subgroups were estimated on a voxel-by-voxel basis. Compared with the CN group, rCMglu was decreased in the bilateral medial temporal regions of the aMCI- subgroup and in the medial temporal cortices as well as the right precuneus of the aMCI+ subgroup. Additionally, rCMglu was lower in the right precuneus of the aMCI+ subgroup compared with the aMCI- subgroup. The present findings indicate that, even though both aMCI subgroups were phenomenologically very similar, the patients with aMCI- exhibited a markedly different regional pattern of functional neurodegeneration compared with the aMCI+ patients.

Keywords: (11)C PiB-PET; (18)F-FDG-PET; Amnestic mild cognitive impairment; Amyloid-beta protein; Neurodegeneration; Regional cerebral glucose metabolism.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amnesia / diagnostic imaging*
  • Amnesia / metabolism
  • Amnesia / pathology
  • Amyloid / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Cerebral Cortex / diagnostic imaging*
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / pathology
  • Cognitive Dysfunction / diagnostic imaging*
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Image Processing, Computer-Assisted
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Positron-Emission Tomography

Substances

  • Amyloid
  • Amyloid beta-Peptides
  • Fluorodeoxyglucose F18